The Response of Diffuse Large Cell and Other Intermediate Grade Non-Hodgkin's Lvmphomas to Adriamvcin Containinr Combination Chemotherapy

References

• The non-Hodgkin's lymphoma classification project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Coleman M. Chemotherapy for large cell lymphoma: optimism and caution. Ann. Intern. Med. 1985; 103: 140–142
   PubMed Web of Science ®Google Scholar
• Gottlieh J.A., Gutterman J.A., McCredle K.B., et al. Chemotherapy of malignant lymphoma with adria-mycin. Cancer Res. 1973; 33: 3024–3028
   PubMed Web of Science ®Google Scholar
• Armitage J.O., Cheson B.D. Interpretation of clinical trials in diffuse large cell lymphoma. J. Clin. Oncol. 1988; 6: 1335–1347
   PubMed Web of Science ®Google Scholar
• Rusthoven J.J. Current approaches of the treatment of advanced stage non-Hodgkin's lymphoma. Can. Med. As-Soc. J. 1987; 136: 29–36
   PubMed Web of Science ®Google Scholar
• Gehan E.A. A generalised Wilcoxon test for comparing arbitrarily single censored samples. Biometrika 1965; 52: 203–223
   PubMed Web of Science ®Google Scholar
• Fisher R.I., Miller T.P., Dana B.W. Southwest Oncology group clinical trials for intermediate and high grade non-Hodgkin's lymphoma. Semi. Hematol. 1987; 2(Suppl. 1)21–25
   Google Scholar
• Armitage J.O., Fyfe M. A. E., Lewis J. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J. Clin. Oncol. 1984; 2: 898–902
   PubMed Web of Science ®Google Scholar
• Schrein P.S., Devita V.T., Jr., Hubbard S., et al. Bleomycin. adriamycin, cyclophosphamide, vincristin and prednison (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann. Intern. Med. 1976; 85: 417–422
   PubMed Web of Science ®Google Scholar
• Lenhard R.E., Ezdinili E.Z., Costello W., et al. Treatment of histiocytic and mixed lymphomas. A comparison of two, three and four drug chemotherapy. Cancer 1978; 42: 41–52
   PubMed Web of Science ®Google Scholar
• Osborn C.K., Young R.C., Garvin A.J. Nodular histiocytic lymphoma: An aggressive nodular lymphoma with potential for prolonged disease free survival. Blood 1980; 56: 98–103
   PubMed Web of Science ®Google Scholar
• Glick J.H., McFadden E., Costello W., et al. Nodular histiocytic lymphoma: Factors influencing prognosis and implications for aggressive chemotherapy. Cancer 1982; 49: 840–845
   PubMed Web of Science ®Google Scholar
• Foucar K., Armitage J.O., Dick F.R. Malignant lymphoma diffuse mixed small and large cell. A clinico pathological study of 47 cases. Cancer 1983; 51: 2090–2099
   PubMed Web of Science ®Google Scholar
• Kantarjian H.M., McLaughlin P., Fuller L.M. Follicular large cell lymphoma: Analysis and prognostic factors in 62 patients. J. Clin. Oncol. 1984; 2: 811–819
   PubMed Web of Science ®Google Scholar
• Dabich L., Ensminger W.D., Zuckerman K.S., et al. High-dose adriamycin combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. Semin. Oncol. 1985; 12(Suppl. 3)212–217
   PubMedGoogle Scholar
• Licht J.D., Bossennan L.D., Anderson J.W., et al. Treatment of low-grade and intermediate grade lymphoma with intensive combination chemotherapy results in long-term, disease free survival. Cancer 1990; 66: 632–639
   PubMed Web of Science ®Google Scholar
• Coiffier B., Byron P.A., French M., et al. Intensive chemotherapy in aggressive lymphomas: Update results of LNH-80 protocol and prognostic factors affecting response and survival. Blood 1987; 70: 1934–1939
   Google Scholar
• Anderson J. R. A., Vose J.M., Bierman P.J., et al. Clinical features and prognosis of follicular large cell lymphoma: A report from the Nebraska lymphoma study group. J. Clin. Oncol. 1993; 11: 218–224
   PubMed Web of Science ®Google Scholar
• Gams R.A., Rainey M., Dandy M., et al. Phase II study of BCOP V CHOP in unfavorable categories of malignant lymphoma. A Southeastern cancer study group. J. Clin. Oncol. 1985; 3: 1188–1195
   PubMed Web of Science ®Google Scholar
• Bishop J.F., Wiernik P.H., Welsley M.N. A randomized trial of high dose cyclophosphamide, vincristin, and prednison plus or minus doxorubicin (CVP versus CAVP) with long-term follow-up in advanced non-Hodgkin's lymphoma. Leukemia 1987; 1: 508–513
   PubMed Web of Science ®Google Scholar
• Kith C.P., Spier C.M., Grogan T.M., et al. Diffuse small cleaved cell lymphoma: A heterogenous disease with distinct immunobiologic subsets. J. Clin. Oncol. 1992; 10: 1259–1265
   PubMed Web of Science ®Google Scholar
• Connors J.M., Kilmo P. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Semin. Hematol. 1988; 25(Suppl. 2)41–46
   PubMed Web of Science ®Google Scholar
• Anderson J.R., Glick J., Ginsberg S., et al. Long-term survival of good prognosis diffuse large cell lymphoma (DLCL) patients treated with CHOP or CHOP variants. Proc. Am. Soc. Clin. Oncol. 1987; 6: 198, (Abstr.)
   Google Scholar
• Cabanilla F., Hagemeister F.B., McLanhlan P., et al. Results of MINE salvage regimen for recurrent or refractory lymphoma. J. Clin. Oncol. 1987; 5: 407–412
   PubMed Web of Science ®Google Scholar
• Valasquez W.S., Cabainllas F., Salvaddor P., et al. Effective salvage therapy for lymphoma in combination with high-dose ARA-C and dexamethazone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• O'Donnell M.R., Forman S.J., Levin A.M., et al. Cytarabin, cisplatinum and etoposide chemotherapy for refractory non-Hodgkin's lymphoma. Cancer Treat. Rep. 1987; 71: 187–189
   PubMedGoogle Scholar
• Annitage J.O. Bone marrow transplantation in the treatment of patients with lymphoma. Blood 1989; 73: 1749–1758
   PubMed Web of Science ®Google Scholar
• Vose J.M., Armitage J.O., Bierman P.J., et al. Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation. Am. J. Med. 1989; 87: 285–288
   PubMed Web of Science ®Google Scholar